Trending at Lumira Ventures

Pharmasset Announces Interim Data from an Ongoing 28-day Phase 2a Study with PSI-7977 for the Treatment of Chronic Hepatitis C Infection

admin Portfolio News, Pharmasset

Source : Pharmasset, Inc. PRINCETON, N.J., April 15 /PRNewswire-FirstCall/ — Pharmasset, Inc. announced today interim efficacy and safety results from its ongoing 28-day phase 2a study with PSI-7977 dosed once daily in combination with Pegasys® (peginterferon alfa 2a) and Copegus® (ribavirin) in …